Antibe Therapeutics Inc(Pre-Merger) ATBPF

RE:RE:RE:RE:RE:RE:RE:comgrats

[WalkOverTheStrt]

Mugsy -

Hard disagree with your below statement. Every dollar Atibe spend on other drugs puts greater risk to Otenal until that one is over the finish line. Valuations on pipeline for animal studies and even PH1 (post results) is minor. This is due to the fact that "90% failure rate is for the drug candidates that are already advanced to phase I clinical trial, which does not include the drug candidates in the preclinical stages. If drug candidates in the preclinical stage are also counted, the failure rate of drug discovery/development is even higher than 90%."   The market in biotechs / acquirers will only minimally value Atibe's other pipeline efforts unless at a min one gets over PH1. Plenty of studies on the drug pipeline inflection point to refer to so I do not agree ""Every additional direction will help generate value going forward - but you need to do the exploratory work and that takes time."  This makes sense if Antibe had the cash reserves / revenue coming in from a commercialized drug but they do not. They owe it to investors to get this one to conclusion and then if they are successful fund exploratory work with the partnership capital/revenues from a successful Otenal. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293739/

O your other points: 
Yes they made a good pivot to accute (one could ask why this was not the initial focus), they hired Dr Joe S who gives confidence and got the reformulation - patent extension done (hopefully it works) which is in the last two years. Let's see them stay on target and run a successful PH2. Access to Dan does not matter in my investment thesis as I judge him/company on past accomplishments/milestones/ect.